Yellow Fever, rDNA (EP+IL-12) and rAd35 as Vectors for AIDS Vaccine Development

描述（由申请人提供）：我们计划探索高度成功的减毒黄热病（YF-17 D）疫苗（通过电穿孔沿着IL-12和rAd 35递送的rDNA）是否可用作载体，以在针对AIDS病毒的疫苗接种的初免/加强方案中表达SIV蛋白。在一系列高度整合的实验中，我们将首先确定疫苗的最佳病毒靶点。然后，我们将把结果汇总在一起，进行最终的功效实验，以测试这些载体，如果成功的话，可以防止数百万人遭受痛苦。 世界各地的人们。我们的申请旨在解决HIVRAD计划公告中概述的十个研究领域中的四个。我们的项目有可能在两个方面影响艾滋病毒疫苗的开发。首先，我们将在挑战实验中确定成功疫苗的靶点。这将使我们能够设计一种疫苗，编码成功免疫反应的关键目标。其次，我们将开发三种全新的疫苗载体。如果我们在这奋进取得成功，我们的结果将对艾滋病毒疫苗的设计产生深远的影响。

DESCRIPTION (provided by applicant): We plan to explore whether the highly successful attenuated yellow fever (YF-17D) vaccine, rDNA delivered by electroporation along with IL-12 and rAd35 can be used as vectors to express SIV proteins in a prime/boost regimen for vaccination against the AIDS virus. In a highly integrated series of experiments, we will first define the best viral targets for a vaccine. We will then bring the results together in a final efficacy experiment to test the vectors that, if successful, could prevent suffering by millions of people worldwide. Our application seeks to address four of the ten research areas outlined in the HIVRAD program announcement. Our project has the potential to impact HIV vaccine development on two fronts. First, we will define the targets of a successful vaccine in a challenge experiment. This will allow us to design a vaccine encoding the critical targets of a successful immune response. Second, we will develop three entirely novel vaccine vectors. If we are successful in this endeavor, our results will have a profound effect on HIV vaccine design.